132691-83-9

Usage

InChI:InChI=1/C12H11Cl2NO4/c13-6-3-7(14)11-5(2-10(16)17)1-9(12(18)19)15-8(11)4-6/h3-5,9,15H,1-2H2,(H,16,17)(H,18,19)

Upstream product

• 141046-79-9 3-Carboxy-2-(3,5-dichlorophenylamino)-propionic acid 
• 132689-81-7 N-(3,5-Dichloro-phenyl)-N-(2,5-dioxo-tetrahydro-furan-3-yl)-acetamide 
• 141046-78-8 methyl 2-(3,5-dichlorophenylamino)-3-methoxycarbonylpropionate 
• 106509-94-8 (E)-2-(3,5-Dichloro-phenylamino)-but-2-enedioic acid dimethyl ester 
• 132689-80-6 1-Acetyl-2-carboxy-5,7-dichloro-4-oxo-1,2,3,4-tetrahydroquinoline 
• 626-43-7 3,5-Dichloroaniline 
• 141046-75-5 5,7-Dichloro-4-methoxycarbonylmethyl-quinoline-2-carboxylic acid methyl ester 

Relevant academic research and scientific papers

Tetrahydroquinoline derivatives useful for neurodegenerative disorders

A class of 1,2,3,4-tetrahydroquinolines possessing at least one substituent, or a spirocyclic moiety, at the 4-position, and an acidic group or a group convertible thereto in vivo at the 2-position, are specific antagonists of N-methyl-D-aspartate (NMDA) receptors and are therefore useful in the treatment and/or prevention of neurodegenerative disorders.

2-Carboxytetrahydroquinolines. Conformational and Stereochemical Requirements for Antagonism of the Glycine Site on the NMDA Receptor

2-Carboxy-1,2,3,4-tetrahydroquinoline derivatives, derived from kynurenic acid, have been synthesized and evaluated for in vitro antagonist activity at the glycine site on the NMDA receptor. 2,3-Dihydrokynurenic acids show reduced potency relative to the